文献速递临床微生物分子诊断

艰难梭菌抗菌药物耐药性更新:耐药机制与药敏试验

Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing.
PubMed 文献 · J Clin Microbiol · 2017-04-12

本文综述了2010年以来艰难梭菌抗菌药物耐药机制的新进展,涵盖可移动遗传元件转移获得的耐药基因、体内选择压力导致的基因突变、氧化还原活性蛋白表达改变、铁代谢与DNA修复异常以及生物膜形成等机制,并讨论了药敏试验方法及应对耐药策略。

要点

  • 艰难梭菌耐药机制包括可移动遗传元件介导的耐药基因获得和基因突变。
  • 氧化还原活性蛋白表达改变、铁代谢和DNA修复异常也参与耐药。
  • 生物膜形成是艰难梭菌耐药的重要机制之一。

核心结论

  • 艰难梭菌对口服抗生素耐药涉及多种表型和基因型机制。

主要发现

  • 耐药机制包括通过可移动遗传元件转移获得耐药基因。
  • 体内选择压力导致基因突变是耐药机制之一。
  • 氧化还原活性蛋白表达改变、铁代谢和DNA修复异常参与耐药。
  • 生物膜形成也是艰难梭菌耐药的重要机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Oral antibiotics such as metronidazole, vancomycin and fidaxomicin are therapies of choice for Clostridium difficile infection. Several important mechanisms for C. difficile antibiotic resistance have been described, including the acquisition of antibiotic resistance genes via the transfer of mobile genetic elements, selective pressure in vivo resulting in gene mutations, altered expression of redox-active proteins, iron metabolism, and DNA repair, as well as via biofilm formation. This update summarizes new information published since 2010 on phenotypic and genotypic resistance mechanisms in C. difficile and addresses susceptibility test methods and other strategies to counter antibiotic resistance of C. difficile.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Peng Z, Jin D, Kim HB, et al. Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing. J Clin Microbiol. 2017. PMID: 28404671. doi:10.1128/JCM.02250-16

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。